| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 98 | 2022 | 2441 | 12.540 |
Why?
|
| Lung Diseases, Interstitial | 34 | 2022 | 213 | 10.550 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 22 | 2022 | 140 | 7.530 |
Why?
|
| Lung | 35 | 2022 | 1092 | 5.130 |
Why?
|
| Radiography, Thoracic | 21 | 2020 | 317 | 3.920 |
Why?
|
| Alveolitis, Extrinsic Allergic | 7 | 2022 | 32 | 3.310 |
Why?
|
| Lung Neoplasms | 25 | 2022 | 2169 | 3.290 |
Why?
|
| Pulmonary Fibrosis | 9 | 2023 | 108 | 2.460 |
Why?
|
| Diagnostic Imaging | 15 | 2022 | 450 | 2.250 |
Why?
|
| Diagnosis, Differential | 33 | 2020 | 1509 | 2.210 |
Why?
|
| Humans | 200 | 2023 | 80913 | 2.170 |
Why?
|
| Lymph Nodes | 7 | 2019 | 509 | 2.120 |
Why?
|
| Radiology | 12 | 2022 | 183 | 2.100 |
Why?
|
| Lung Diseases | 10 | 2021 | 255 | 1.830 |
Why?
|
| Solitary Pulmonary Nodule | 6 | 2022 | 136 | 1.760 |
Why?
|
| Computed Tomography Angiography | 9 | 2020 | 107 | 1.720 |
Why?
|
| Connective Tissue Diseases | 5 | 2021 | 62 | 1.670 |
Why?
|
| Middle Aged | 84 | 2021 | 23968 | 1.630 |
Why?
|
| Practice Guidelines as Topic | 11 | 2020 | 1013 | 1.610 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2021 | 349 | 1.600 |
Why?
|
| Idiopathic Interstitial Pneumonias | 9 | 2019 | 28 | 1.570 |
Why?
|
| Aged | 66 | 2023 | 17480 | 1.530 |
Why?
|
| Dyspnea | 5 | 2020 | 64 | 1.510 |
Why?
|
| Incidental Findings | 5 | 2018 | 91 | 1.490 |
Why?
|
| Utilization Review | 2 | 2019 | 19 | 1.420 |
Why?
|
| Pulmonologists | 2 | 2018 | 4 | 1.390 |
Why?
|
| Male | 91 | 2023 | 39425 | 1.390 |
Why?
|
| Circulating Tumor DNA | 4 | 2022 | 23 | 1.380 |
Why?
|
| Female | 92 | 2023 | 42468 | 1.370 |
Why?
|
| Coronary Artery Disease | 8 | 2020 | 319 | 1.330 |
Why?
|
| Multiple Pulmonary Nodules | 3 | 2018 | 6 | 1.300 |
Why?
|
| Thoracic Injuries | 6 | 2020 | 29 | 1.280 |
Why?
|
| Wounds, Nonpenetrating | 4 | 2020 | 82 | 1.260 |
Why?
|
| Radiology Department, Hospital | 2 | 2018 | 27 | 1.250 |
Why?
|
| Cough | 3 | 2020 | 48 | 1.230 |
Why?
|
| Interdisciplinary Communication | 2 | 2018 | 124 | 1.210 |
Why?
|
| Societies, Medical | 17 | 2021 | 564 | 1.210 |
Why?
|
| Aortic Diseases | 3 | 2019 | 97 | 1.180 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 157 | 1.160 |
Why?
|
| Aorta, Thoracic | 3 | 2019 | 161 | 1.150 |
Why?
|
| Biopsy | 9 | 2021 | 1126 | 1.140 |
Why?
|
| Genomics | 12 | 2021 | 650 | 1.080 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2021 | 3116 | 1.060 |
Why?
|
| Reproducibility of Results | 13 | 2021 | 2583 | 1.020 |
Why?
|
| Scleroderma, Systemic | 3 | 2020 | 38 | 1.010 |
Why?
|
| BRCA2 Protein | 3 | 2021 | 137 | 0.980 |
Why?
|
| Sensitivity and Specificity | 14 | 2021 | 1939 | 0.980 |
Why?
|
| Teleradiology | 1 | 2022 | 4 | 0.940 |
Why?
|
| Mediastinum | 3 | 2019 | 46 | 0.930 |
Why?
|
| Contrast Media | 14 | 2019 | 1023 | 0.930 |
Why?
|
| Mucin-5B | 3 | 2019 | 11 | 0.920 |
Why?
|
| Retrospective Studies | 28 | 2022 | 7560 | 0.910 |
Why?
|
| Carcinoma, Transitional Cell | 6 | 2020 | 157 | 0.900 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2019 | 181 | 0.890 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 1605 | 0.880 |
Why?
|
| Coronary Angiography | 9 | 2019 | 205 | 0.870 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 1019 | 0.850 |
Why?
|
| Phthalazines | 2 | 2018 | 36 | 0.840 |
Why?
|
| Radiology Information Systems | 3 | 2018 | 78 | 0.840 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2018 | 63 | 0.830 |
Why?
|
| Pulmonary Embolism | 3 | 2020 | 199 | 0.830 |
Why?
|
| Psoriasis | 6 | 2020 | 229 | 0.830 |
Why?
|
| Pleura | 3 | 2020 | 30 | 0.820 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2019 | 15 | 0.820 |
Why?
|
| Positron Emission Tomography Computed Tomography | 7 | 2021 | 72 | 0.820 |
Why?
|
| Fluorodeoxyglucose F18 | 9 | 2018 | 124 | 0.810 |
Why?
|
| Adult | 50 | 2023 | 24643 | 0.800 |
Why?
|
| Pulmonary Artery | 4 | 2019 | 285 | 0.800 |
Why?
|
| Piperazines | 3 | 2020 | 261 | 0.790 |
Why?
|
| Survival Analysis | 5 | 2018 | 1514 | 0.790 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 467 | 0.790 |
Why?
|
| Radiologists | 3 | 2020 | 40 | 0.780 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 350 | 0.780 |
Why?
|
| B7-H1 Antigen | 2 | 2021 | 223 | 0.770 |
Why?
|
| Cohort Studies | 15 | 2023 | 2583 | 0.760 |
Why?
|
| Radiopharmaceuticals | 8 | 2018 | 159 | 0.760 |
Why?
|
| Quality Assurance, Health Care | 2 | 2018 | 223 | 0.750 |
Why?
|
| Pleural Diseases | 2 | 2016 | 11 | 0.730 |
Why?
|
| Positron-Emission Tomography | 6 | 2016 | 277 | 0.730 |
Why?
|
| Granuloma | 3 | 2016 | 62 | 0.720 |
Why?
|
| Pulmonary Alveoli | 2 | 2016 | 72 | 0.700 |
Why?
|
| United States | 25 | 2021 | 6171 | 0.690 |
Why?
|
| Pneumonia, Bacterial | 2 | 2016 | 26 | 0.690 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 17 | 0.680 |
Why?
|
| Autoimmune Diseases | 2 | 2017 | 230 | 0.670 |
Why?
|
| Urothelium | 1 | 2018 | 62 | 0.670 |
Why?
|
| Feedback | 1 | 2018 | 120 | 0.650 |
Why?
|
| Technology, Radiologic | 1 | 2018 | 102 | 0.650 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 1409 | 0.640 |
Why?
|
| Prognosis | 15 | 2021 | 3546 | 0.640 |
Why?
|
| Gadolinium | 3 | 2014 | 96 | 0.630 |
Why?
|
| Evidence-Based Medicine | 13 | 2021 | 418 | 0.620 |
Why?
|
| Physician Incentive Plans | 1 | 2016 | 21 | 0.620 |
Why?
|
| Efficiency | 1 | 2016 | 38 | 0.620 |
Why?
|
| Speech Recognition Software | 1 | 2016 | 5 | 0.610 |
Why?
|
| Prevalence | 8 | 2021 | 1182 | 0.610 |
Why?
|
| Medical Audit | 1 | 2016 | 39 | 0.600 |
Why?
|
| Tracheomalacia | 1 | 2016 | 2 | 0.600 |
Why?
|
| Peer Review | 1 | 2016 | 23 | 0.600 |
Why?
|
| Medical Records | 1 | 2016 | 114 | 0.590 |
Why?
|
| Fibrosis | 6 | 2020 | 190 | 0.590 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2016 | 5 | 0.590 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2016 | 31 | 0.580 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2013 | 151 | 0.580 |
Why?
|
| Gases | 1 | 2015 | 28 | 0.570 |
Why?
|
| Breast Implants | 1 | 2015 | 21 | 0.560 |
Why?
|
| Birt-Hogg-Dube Syndrome | 2 | 2014 | 3 | 0.560 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2020 | 126 | 0.560 |
Why?
|
| Calcinosis | 1 | 2016 | 220 | 0.560 |
Why?
|
| Lymphangioleiomyomatosis | 2 | 2014 | 8 | 0.550 |
Why?
|
| Cryptogenic Organizing Pneumonia | 2 | 2012 | 5 | 0.550 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2014 | 18 | 0.550 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 361 | 0.550 |
Why?
|
| Mutation | 11 | 2022 | 3793 | 0.550 |
Why?
|
| Tracheal Diseases | 2 | 2013 | 12 | 0.550 |
Why?
|
| Lung Transplantation | 2 | 2018 | 168 | 0.540 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 424 | 0.540 |
Why?
|
| Faculty, Medical | 1 | 2016 | 171 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 906 | 0.530 |
Why?
|
| Carcinoma | 1 | 2018 | 422 | 0.530 |
Why?
|
| Cysts | 2 | 2014 | 92 | 0.520 |
Why?
|
| Lymphatic Diseases | 1 | 2014 | 35 | 0.520 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2014 | 18 | 0.510 |
Why?
|
| Motivation | 1 | 2016 | 272 | 0.510 |
Why?
|
| Pulmonary Valve | 2 | 2020 | 30 | 0.500 |
Why?
|
| Chronic Disease | 7 | 2020 | 942 | 0.500 |
Why?
|
| Observer Variation | 4 | 2020 | 587 | 0.500 |
Why?
|
| Sarcoidosis | 1 | 2014 | 67 | 0.500 |
Why?
|
| Testicular Neoplasms | 3 | 2019 | 101 | 0.490 |
Why?
|
| Disease Progression | 7 | 2021 | 1435 | 0.490 |
Why?
|
| Aorta | 3 | 2020 | 273 | 0.480 |
Why?
|
| Pulmonary Circulation | 2 | 2012 | 84 | 0.480 |
Why?
|
| Mass Screening | 1 | 2017 | 597 | 0.480 |
Why?
|
| Ventricular Septum | 1 | 2012 | 11 | 0.470 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2021 | 153 | 0.470 |
Why?
|
| Cystectomy | 5 | 2021 | 84 | 0.470 |
Why?
|
| Image Enhancement | 2 | 2013 | 549 | 0.470 |
Why?
|
| Pulmonary Subvalvular Stenosis | 1 | 2012 | 1 | 0.470 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 66 | 0.460 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2020 | 1046 | 0.460 |
Why?
|
| Echocardiography | 4 | 2020 | 874 | 0.450 |
Why?
|
| Systole | 1 | 2012 | 128 | 0.450 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 153 | 0.450 |
Why?
|
| Aneurysm | 1 | 2012 | 54 | 0.450 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2011 | 5 | 0.440 |
Why?
|
| Smoking | 3 | 2017 | 594 | 0.430 |
Why?
|
| Kidney Neoplasms | 4 | 2021 | 588 | 0.430 |
Why?
|
| Lymphadenopathy | 2 | 2021 | 15 | 0.430 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 6214 | 0.430 |
Why?
|
| Pulmonary Infarction | 1 | 2010 | 1 | 0.420 |
Why?
|
| Immunocompromised Host | 3 | 2019 | 133 | 0.410 |
Why?
|
| Hematoma | 1 | 2011 | 89 | 0.410 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 302 | 0.410 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 286 | 0.410 |
Why?
|
| Inhalation Exposure | 2 | 2021 | 28 | 0.410 |
Why?
|
| Lung Diseases, Fungal | 1 | 2010 | 18 | 0.400 |
Why?
|
| Mucormycosis | 1 | 2010 | 14 | 0.400 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 421 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 258 | 0.390 |
Why?
|
| Mitral Valve | 1 | 2012 | 238 | 0.390 |
Why?
|
| Phenotype | 7 | 2019 | 2287 | 0.390 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 2277 | 0.380 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2019 | 40 | 0.380 |
Why?
|
| Graft Rejection | 1 | 2016 | 1044 | 0.380 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2009 | 4 | 0.380 |
Why?
|
| Amyloidosis | 1 | 2010 | 88 | 0.380 |
Why?
|
| Heart Diseases | 1 | 2012 | 287 | 0.370 |
Why?
|
| Adenocarcinoma | 4 | 2020 | 1125 | 0.370 |
Why?
|
| Colorado | 3 | 2019 | 33 | 0.360 |
Why?
|
| Radiographic Image Enhancement | 4 | 2016 | 461 | 0.360 |
Why?
|
| Receptor, ErbB-2 | 3 | 2020 | 198 | 0.360 |
Why?
|
| Betacoronavirus | 3 | 2020 | 245 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2348 | 0.350 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 266 | 0.350 |
Why?
|
| Inflammation | 3 | 2018 | 845 | 0.340 |
Why?
|
| Asthma | 1 | 2016 | 913 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 5 | 2021 | 516 | 0.330 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2021 | 402 | 0.320 |
Why?
|
| Heart Defects, Congenital | 2 | 2018 | 338 | 0.320 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 90 | 0.320 |
Why?
|
| Feasibility Studies | 4 | 2022 | 725 | 0.320 |
Why?
|
| Respiratory Tract Infections | 3 | 2019 | 99 | 0.320 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1328 | 0.310 |
Why?
|
| Respiratory Tract Diseases | 2 | 2018 | 45 | 0.310 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 230 | 0.310 |
Why?
|
| Gene Rearrangement | 4 | 2020 | 167 | 0.310 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 406 | 0.310 |
Why?
|
| Genotype | 4 | 2017 | 1812 | 0.300 |
Why?
|
| Respiratory-Gated Imaging Techniques | 2 | 2016 | 4 | 0.300 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 961 | 0.300 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 778 | 0.290 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 313 | 0.280 |
Why?
|
| Algorithms | 7 | 2019 | 1776 | 0.280 |
Why?
|
| DiGeorge Syndrome | 2 | 2017 | 14 | 0.280 |
Why?
|
| Atherosclerosis | 2 | 2018 | 223 | 0.280 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 645 | 0.280 |
Why?
|
| Anthracosis | 2 | 2022 | 2 | 0.270 |
Why?
|
| Rheumatoid Factor | 2 | 2021 | 24 | 0.260 |
Why?
|
| Stroke | 1 | 2012 | 769 | 0.260 |
Why?
|
| Prospective Studies | 10 | 2023 | 3927 | 0.260 |
Why?
|
| Treatment Outcome | 10 | 2020 | 7498 | 0.260 |
Why?
|
| Risk Factors | 10 | 2021 | 5137 | 0.260 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 1886 | 0.260 |
Why?
|
| Thoracic Wall | 2 | 2021 | 22 | 0.250 |
Why?
|
| Angiography | 3 | 2014 | 200 | 0.250 |
Why?
|
| Hypertension, Pulmonary | 3 | 2018 | 325 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1164 | 0.250 |
Why?
|
| Carcinoma, Bronchogenic | 2 | 2013 | 30 | 0.240 |
Why?
|
| Biological Specimen Banks | 2 | 2020 | 56 | 0.240 |
Why?
|
| Hemoptysis | 2 | 2014 | 23 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 602 | 0.230 |
Why?
|
| Multidetector Computed Tomography | 3 | 2019 | 51 | 0.230 |
Why?
|
| Software | 3 | 2018 | 640 | 0.230 |
Why?
|
| Serologic Tests | 2 | 2020 | 41 | 0.220 |
Why?
|
| Genetic Variation | 2 | 2019 | 1340 | 0.220 |
Why?
|
| Medical History Taking | 2 | 2020 | 81 | 0.220 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 20 | 0.220 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2019 | 41 | 0.220 |
Why?
|
| Urethral Neoplasms | 1 | 2021 | 9 | 0.220 |
Why?
|
| Carcinoma, Medullary | 1 | 2021 | 11 | 0.210 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 47 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 561 | 0.210 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 2764 | 0.210 |
Why?
|
| Myocardial Contusions | 1 | 2020 | 1 | 0.210 |
Why?
|
| Oncogene Fusion | 1 | 2020 | 7 | 0.210 |
Why?
|
| Atrial Septum | 2 | 2010 | 9 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 5 | 2021 | 274 | 0.210 |
Why?
|
| Urogenital Neoplasms | 1 | 2020 | 20 | 0.210 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2020 | 2 | 0.200 |
Why?
|
| Vaping | 1 | 2021 | 28 | 0.200 |
Why?
|
| Occupational Health | 1 | 2021 | 32 | 0.200 |
Why?
|
| Ureteral Neoplasms | 1 | 2020 | 13 | 0.200 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 11 | 0.200 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 558 | 0.200 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 22 | 0.200 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2020 | 1 | 0.200 |
Why?
|
| Gastropexy | 1 | 2020 | 1 | 0.200 |
Why?
|
| Receptors, Androgen | 1 | 2021 | 91 | 0.200 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 60 | 0.200 |
Why?
|
| Registries | 3 | 2021 | 646 | 0.200 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2010 | 62 | 0.200 |
Why?
|
| Ossification, Heterotopic | 1 | 2020 | 31 | 0.200 |
Why?
|
| Bronchiolitis | 3 | 2015 | 4 | 0.200 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2020 | 3 | 0.200 |
Why?
|
| Risk Assessment | 5 | 2021 | 2173 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2021 | 75 | 0.200 |
Why?
|
| Parenchymal Tissue | 1 | 2020 | 6 | 0.200 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 122 | 0.200 |
Why?
|
| Radiation Dosage | 2 | 2019 | 224 | 0.200 |
Why?
|
| Internship and Residency | 1 | 2009 | 929 | 0.190 |
Why?
|
| Pandemics | 3 | 2020 | 628 | 0.190 |
Why?
|
| France | 1 | 2020 | 45 | 0.190 |
Why?
|
| Survival Rate | 3 | 2019 | 1814 | 0.190 |
Why?
|
| Piperidines | 2 | 2018 | 177 | 0.190 |
Why?
|
| Brazil | 1 | 2020 | 68 | 0.190 |
Why?
|
| Genome | 2 | 2020 | 348 | 0.190 |
Why?
|
| Coronavirus | 1 | 2020 | 18 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 2303 | 0.190 |
Why?
|
| Gastrostomy | 1 | 2020 | 65 | 0.190 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 28 | 0.190 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 261 | 0.190 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 106 | 0.190 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 92 | 0.190 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 181 | 0.190 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 43 | 0.190 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 79 | 0.190 |
Why?
|
| Autoimmunity | 2 | 2018 | 157 | 0.190 |
Why?
|
| Hemorrhage | 1 | 2021 | 233 | 0.180 |
Why?
|
| Medicare Part B | 1 | 2019 | 3 | 0.180 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 16 | 0.180 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 39 | 0.180 |
Why?
|
| Arthritis, Psoriatic | 1 | 2019 | 29 | 0.180 |
Why?
|
| Referral and Consultation | 2 | 2019 | 303 | 0.180 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 75 | 0.180 |
Why?
|
| Hematopoietic System | 1 | 2018 | 13 | 0.180 |
Why?
|
| Artifacts | 3 | 2019 | 237 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 18 | 0.180 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 44 | 0.180 |
Why?
|
| Rheumatologists | 1 | 2018 | 5 | 0.180 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 47 | 0.180 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 44 | 0.180 |
Why?
|
| Seminoma | 1 | 2018 | 8 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 75 | 0.180 |
Why?
|
| Quinazolines | 2 | 2018 | 217 | 0.180 |
Why?
|
| Databases, Factual | 2 | 2020 | 762 | 0.180 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 126 | 0.180 |
Why?
|
| Bronchoscopy | 5 | 2021 | 142 | 0.180 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 39 | 0.180 |
Why?
|
| Pathologists | 1 | 2018 | 19 | 0.170 |
Why?
|
| Parathyroid Neoplasms | 1 | 2018 | 53 | 0.170 |
Why?
|
| Autoantibodies | 1 | 2019 | 256 | 0.170 |
Why?
|
| Statistics as Topic | 2 | 2017 | 231 | 0.170 |
Why?
|
| Comparative Effectiveness Research | 2 | 2016 | 44 | 0.170 |
Why?
|
| Carbazoles | 1 | 2018 | 51 | 0.170 |
Why?
|
| Lipoproteins, HDL | 1 | 2018 | 94 | 0.170 |
Why?
|
| Amygdala | 1 | 2018 | 78 | 0.170 |
Why?
|
| Drug Substitution | 1 | 2018 | 27 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2020 | 462 | 0.170 |
Why?
|
| Occupational Diseases | 2 | 2016 | 51 | 0.170 |
Why?
|
| Pneumonectomy | 1 | 2020 | 191 | 0.170 |
Why?
|
| Pulmonary Emphysema | 1 | 2017 | 21 | 0.170 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 58 | 0.170 |
Why?
|
| Vasculitis | 1 | 2017 | 38 | 0.170 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 16 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 68 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 525 | 0.170 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 30 | 0.160 |
Why?
|
| Acetylcysteine | 1 | 2018 | 69 | 0.160 |
Why?
|
| Coronary Vessels | 1 | 2019 | 167 | 0.160 |
Why?
|
| Tetralogy of Fallot | 1 | 2017 | 43 | 0.160 |
Why?
|
| Adiposity | 1 | 2017 | 68 | 0.160 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1742 | 0.160 |
Why?
|
| Antirheumatic Agents | 1 | 2017 | 48 | 0.160 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 216 | 0.160 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2019 | 460 | 0.160 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2016 | 22 | 0.160 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 32 | 0.160 |
Why?
|
| Transcriptome | 1 | 2021 | 527 | 0.160 |
Why?
|
| Biological Products | 1 | 2019 | 133 | 0.160 |
Why?
|
| Machine Learning | 1 | 2019 | 200 | 0.160 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 18 | 0.150 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2016 | 2 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 94 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 110 | 0.150 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 56 | 0.150 |
Why?
|
| Software Validation | 1 | 2016 | 3 | 0.150 |
Why?
|
| Neutrophils | 1 | 2018 | 296 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2018 | 189 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2019 | 397 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 917 | 0.150 |
Why?
|
| Mycobacterium avium Complex | 1 | 2016 | 6 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 349 | 0.150 |
Why?
|
| Azathioprine | 1 | 2016 | 121 | 0.150 |
Why?
|
| Myositis | 1 | 2016 | 16 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 152 | 0.150 |
Why?
|
| Atmospheric Pressure | 1 | 2015 | 2 | 0.150 |
Why?
|
| Time Factors | 6 | 2021 | 5094 | 0.150 |
Why?
|
| Hospitalization | 2 | 2018 | 768 | 0.140 |
Why?
|
| Stress, Psychological | 1 | 2018 | 292 | 0.140 |
Why?
|
| Altitude | 1 | 2015 | 42 | 0.140 |
Why?
|
| Neuroendocrine Cells | 1 | 2015 | 2 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 248 | 0.140 |
Why?
|
| Rib Fractures | 1 | 2014 | 6 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2018 | 658 | 0.140 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 682 | 0.140 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 107 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2016 | 214 | 0.140 |
Why?
|
| Cystic Fibrosis | 1 | 2016 | 114 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 2020 | 731 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 948 | 0.130 |
Why?
|
| Heterozygote | 1 | 2016 | 359 | 0.130 |
Why?
|
| Pneumonia, Aspiration | 1 | 2014 | 18 | 0.130 |
Why?
|
| Acute Disease | 4 | 2019 | 805 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 231 | 0.130 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2014 | 25 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2018 | 363 | 0.130 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 232 | 0.130 |
Why?
|
| Emphysema | 1 | 2014 | 14 | 0.130 |
Why?
|
| Glass | 1 | 2014 | 14 | 0.130 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2014 | 7 | 0.130 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 967 | 0.130 |
Why?
|
| Young Adult | 6 | 2021 | 5728 | 0.130 |
Why?
|
| User-Computer Interface | 2 | 2012 | 183 | 0.130 |
Why?
|
| Bronchial Diseases | 1 | 2013 | 11 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2016 | 268 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 1692 | 0.120 |
Why?
|
| Antibodies, Antinuclear | 3 | 2018 | 82 | 0.120 |
Why?
|
| Comorbidity | 1 | 2017 | 915 | 0.120 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 97 | 0.120 |
Why?
|
| Thorax | 1 | 2013 | 56 | 0.120 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 1534 | 0.120 |
Why?
|
| Protons | 1 | 2013 | 93 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 683 | 0.120 |
Why?
|
| Phantoms, Imaging | 2 | 2014 | 426 | 0.120 |
Why?
|
| Mediastinitis | 1 | 2012 | 14 | 0.120 |
Why?
|
| Cleft Palate | 1 | 2012 | 25 | 0.120 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2017 | 23 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2012 | 23 | 0.120 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 54 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 1527 | 0.110 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2012 | 19 | 0.110 |
Why?
|
| Chicago | 1 | 2017 | 1344 | 0.110 |
Why?
|
| Vital Capacity | 3 | 2017 | 61 | 0.110 |
Why?
|
| Critical Care | 1 | 2015 | 351 | 0.110 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2012 | 36 | 0.110 |
Why?
|
| Pericarditis, Constrictive | 1 | 2012 | 5 | 0.110 |
Why?
|
| Alleles | 1 | 2016 | 1093 | 0.110 |
Why?
|
| Cardiac Tamponade | 1 | 2012 | 16 | 0.110 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2012 | 8 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2011 | 23 | 0.110 |
Why?
|
| Heart Septum | 1 | 2012 | 45 | 0.110 |
Why?
|
| Thoracic Diseases | 1 | 2012 | 25 | 0.110 |
Why?
|
| Atlases as Topic | 1 | 2011 | 6 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1368 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 812 | 0.110 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 97 | 0.110 |
Why?
|
| Tomography, Spiral Computed | 1 | 2011 | 74 | 0.100 |
Why?
|
| Bronchiectasis | 1 | 2010 | 12 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 291 | 0.100 |
Why?
|
| Adolescent | 5 | 2021 | 8669 | 0.100 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 221 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2011 | 204 | 0.100 |
Why?
|
| Hypotension | 1 | 2010 | 65 | 0.100 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2012 | 182 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2012 | 237 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 843 | 0.100 |
Why?
|
| Fever | 1 | 2010 | 122 | 0.100 |
Why?
|
| Logistic Models | 3 | 2018 | 1112 | 0.100 |
Why?
|
| Bacteremia | 1 | 2010 | 95 | 0.100 |
Why?
|
| Italy | 2 | 2021 | 102 | 0.090 |
Why?
|
| Trachea | 1 | 2011 | 292 | 0.090 |
Why?
|
| Delphi Technique | 3 | 2014 | 60 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3534 | 0.090 |
Why?
|
| Child | 4 | 2023 | 6545 | 0.090 |
Why?
|
| MCF-7 Cells | 2 | 2020 | 103 | 0.090 |
Why?
|
| Washington | 1 | 2009 | 47 | 0.090 |
Why?
|
| Biomarkers | 3 | 2021 | 1603 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 1423 | 0.090 |
Why?
|
| Respiratory Function Tests | 2 | 2019 | 130 | 0.090 |
Why?
|
| Professional Competence | 1 | 2009 | 65 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 376 | 0.090 |
Why?
|
| INDEL Mutation | 2 | 2018 | 30 | 0.090 |
Why?
|
| Palliative Care | 1 | 2010 | 234 | 0.090 |
Why?
|
| HIV Infections | 1 | 2016 | 667 | 0.090 |
Why?
|
| Chest Pain | 2 | 2021 | 36 | 0.090 |
Why?
|
| Liquid Biopsy | 2 | 2018 | 28 | 0.090 |
Why?
|
| Lung Injury | 2 | 2021 | 44 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 439 | 0.080 |
Why?
|
| Pyridines | 2 | 2020 | 299 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 539 | 0.080 |
Why?
|
| Cholesterol, HDL | 2 | 2018 | 163 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 2324 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2020 | 374 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2010 | 219 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 519 | 0.080 |
Why?
|
| ErbB Receptors | 2 | 2020 | 475 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 675 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 843 | 0.070 |
Why?
|
| Patient Selection | 2 | 2020 | 661 | 0.070 |
Why?
|
| Forced Expiratory Volume | 2 | 2015 | 116 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2021 | 652 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 558 | 0.070 |
Why?
|
| Neoplasms | 1 | 2019 | 2688 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 824 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 1166 | 0.060 |
Why?
|
| ROC Curve | 2 | 2019 | 734 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 3524 | 0.060 |
Why?
|
| Iopamidol | 2 | 2013 | 8 | 0.060 |
Why?
|
| Radiography | 2 | 2016 | 790 | 0.060 |
Why?
|
| CD57 Antigens | 1 | 2021 | 5 | 0.060 |
Why?
|
| CD56 Antigen | 1 | 2021 | 18 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 118 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2019 | 3148 | 0.050 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 26 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2020 | 22 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2020 | 105 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2020 | 36 | 0.050 |
Why?
|
| New York | 1 | 2020 | 67 | 0.050 |
Why?
|
| Cryosurgery | 1 | 2020 | 33 | 0.050 |
Why?
|
| Psychotropic Drugs | 1 | 2021 | 74 | 0.050 |
Why?
|
| Dronabinol | 1 | 2021 | 47 | 0.050 |
Why?
|
| Muscles | 1 | 2021 | 184 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2020 | 50 | 0.050 |
Why?
|
| Nicotinic Agonists | 1 | 2021 | 72 | 0.050 |
Why?
|
| Ontario | 1 | 2020 | 51 | 0.050 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2021 | 48 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 300 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 125 | 0.050 |
Why?
|
| Body Composition | 1 | 2020 | 63 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2020 | 151 | 0.050 |
Why?
|
| North America | 1 | 2020 | 174 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2192 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2021 | 497 | 0.050 |
Why?
|
| Animals | 3 | 2018 | 25631 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2021 | 473 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2021 | 274 | 0.050 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 51 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 131 | 0.050 |
Why?
|
| Organ Size | 1 | 2020 | 349 | 0.050 |
Why?
|
| Genomic Structural Variation | 1 | 2019 | 3 | 0.050 |
Why?
|
| Telomerase | 1 | 2019 | 52 | 0.050 |
Why?
|
| Nicotine | 1 | 2021 | 191 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 57 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 307 | 0.050 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2018 | 3 | 0.050 |
Why?
|
| Radiation Exposure | 1 | 2019 | 21 | 0.050 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 2018 | 8 | 0.050 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2018 | 4 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 7 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2020 | 175 | 0.050 |
Why?
|
| Equipment Design | 1 | 2020 | 400 | 0.040 |
Why?
|
| Motion | 1 | 2019 | 80 | 0.040 |
Why?
|
| Necrosis | 1 | 2019 | 190 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 296 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2018 | 104 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 50 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 38 | 0.040 |
Why?
|
| Anilides | 1 | 2018 | 45 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2018 | 45 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 650 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 444 | 0.040 |
Why?
|
| Hospitals | 1 | 2020 | 218 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2019 | 154 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 447 | 0.040 |
Why?
|
| MEF2 Transcription Factors | 1 | 2017 | 8 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 646 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2018 | 130 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 265 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 279 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 136 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 84 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 142 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 220 | 0.040 |
Why?
|
| Proteome | 1 | 2018 | 107 | 0.040 |
Why?
|
| Phototherapy | 1 | 2017 | 35 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 248 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2018 | 206 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 169 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 133 | 0.040 |
Why?
|
| Whole Body Imaging | 1 | 2017 | 39 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 108 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1539 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2017 | 283 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 272 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 656 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2018 | 586 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 150 | 0.040 |
Why?
|
| Pneumocystis carinii | 1 | 2016 | 3 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 752 | 0.040 |
Why?
|
| Hypersplenism | 1 | 2016 | 2 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 183 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 919 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 667 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 204 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 80 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 354 | 0.040 |
Why?
|
| Leukopenia | 1 | 2016 | 65 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2016 | 95 | 0.040 |
Why?
|
| Heart Rate | 1 | 2019 | 476 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2016 | 48 | 0.040 |
Why?
|
| Silicosis | 1 | 2016 | 1 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 214 | 0.040 |
Why?
|
| Asbestosis | 1 | 2016 | 5 | 0.040 |
Why?
|
| Protein Domains | 1 | 2016 | 123 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2020 | 354 | 0.040 |
Why?
|
| Arthritis | 1 | 2016 | 45 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 365 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2017 | 238 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 465 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 1036 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 336 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2020 | 618 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2016 | 349 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1183 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 392 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2273 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 1067 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2016 | 173 | 0.040 |
Why?
|
| Physical Examination | 1 | 2016 | 140 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 680 | 0.030 |
Why?
|
| Chromatin | 1 | 2017 | 336 | 0.030 |
Why?
|
| Lung Abscess | 1 | 2014 | 5 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 743 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 307 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 2929 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2015 | 144 | 0.030 |
Why?
|
| Multiple Trauma | 1 | 2014 | 32 | 0.030 |
Why?
|
| Mice | 2 | 2018 | 10812 | 0.030 |
Why?
|
| Diaphragm | 1 | 2014 | 49 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2014 | 44 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1939 | 0.030 |
Why?
|
| Aortography | 1 | 2014 | 57 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 89 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 2014 | 58 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 831 | 0.030 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2013 | 13 | 0.030 |
Why?
|
| Evidence-Based Dentistry | 1 | 2013 | 10 | 0.030 |
Why?
|
| Bronchial Neoplasms | 1 | 2013 | 9 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 130 | 0.030 |
Why?
|
| Tracheal Neoplasms | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2429 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2016 | 872 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 678 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2014 | 108 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 358 | 0.030 |
Why?
|
| Gene Order | 1 | 2012 | 22 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1714 | 0.030 |
Why?
|
| Health Policy | 1 | 2014 | 172 | 0.030 |
Why?
|
| Inpatients | 1 | 2015 | 276 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 2059 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2284 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 1187 | 0.030 |
Why?
|
| Collagen Diseases | 1 | 2012 | 3 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2015 | 347 | 0.030 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2012 | 3 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 27 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2013 | 185 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2011 | 12 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 206 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 422 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2012 | 55 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2011 | 48 | 0.030 |
Why?
|
| Diastole | 1 | 2012 | 140 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2013 | 282 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 641 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 198 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2011 | 326 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 984 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2012 | 214 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2064 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1045 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 959 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2313 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 466 | 0.020 |
Why?
|